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Summary
Genetic studies of calcium kidney stones evidenced the pos-
sible involvement of calcium-sensing receptor gene, vitamin D
receptor gene and bicarbonate-sensitive adenylate cyclase
gene, but it is uncertain which specific polymorphisms could
be responsible. Thus, further studies are required to better as-
sess the involvement of these or other genes and the interac-
tions between different genes and between genes and envi-
ronment. In addition to research in humans, the study of dif-
ferent strains of knock-out mice let us include the gene of
phosphate reabsorption carrier NPT2, caveolin-1, protein
NHERF-1, osteopontin and Tamm-Horsfall protein among the
possible determinants. Further steps in the knowledge of cal-
cium stone causes may be done using the instruments that
the modern biotechnology and bioinformatics have made
available to the researchers.
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Introduction
Current clinical and epidemiologic data support the inclusion of
nephrolithiasis among complex diseases, such as diabetes, hy-
pertension and ischemic heart disease. Complex diseases are
the most prevalent disorders in modern Western society and the
greatest burden for National Health Care Systems. In Italy
nephrolitiasis is the leading cause of hospitalization for nephro-
logic and urologic diseases (~ 100.000 hospitalizations a year in
the last decade), accounting for an annual expenditure of 250
million euros by the Italian Health Care System (data from the
Italian Health Ministry website, http://www.ministerosalute.it/). As
for other complex diseases, nephrolithiasis is likely caused by
the interaction of multiple genetic and environmental factors (1). 
This picture is sufficient to highlight the importance of preven-
tion in kidney stone disease. The ability to identify individuals at
risk of stones would allow implementation of measures to pre-
vent kidney stones and their potential complications among
susceptible individuals. However, no validated markers of sus-
ceptibility to kidney stones are presently available, and great
hopes are placed in genetic research.
The importance of a genetic background in the development of
nephrolithiasis has emerged from studies in North-American
and European families showing a higher prevalence of kidney
stones among first degree relatives of stone-forming patients
then among first degree relatives of non-stone formers (2-5).
The comparative study of monozygous and dizygous twins
born in Vietnam showed a greater concordance for stone pro-
duction among monozygotes than dizygotes (32.4% vs.
17.3%). This study estimated that in the population of Vietnam
the proportion of kidney stone susceptibility attributable to ge-
netic causes was 56%, while environmental causes explained
44% of the disease (6).
In the Western world  80% of kidney stones are made of calci-
um oxalate and calcium phosphate. Thus, calcium stones ac-
count for the majority of the economic and epidemiologic bur-
den of nephrolithiasis. Thus, the present article focuses on re-
search findings concerning calcium nephrolithiasis in animals
and humans.
Studies on animals with kidney stones
Knock-out mice are created to lack the expression of a specific
gene product  through gene silencing. The assessment of the
resulting phenotype provides important functional information
about the silenced gene. Therefore, stone forming knock-out
mice represent an important tool to understand which genes
may be important for the development of calcium nephrolithia-
sis.
Five different strains of knock-out mice are known to develop
phenotypes featuring calcium stones or kidney calcifications.
The first is a knock-out strain for the carrier excreting oxalates
into the intestinal lumen (slc26a13) (7). The absence of the in-
testinal oxalate carrier results in body accumulation of oxalate,
increased urinary oxalate execretion, precipitation of calcium-
oxalate in the urine and formation of kidney stones. 
The second strain is knock-out for the caveolin-1 gene (cav-1).
It lacks of caveolae, that are invaginations of the plasma mem-
brane of kidney tubular cells. Caveolae are functional hot-
points within the plasma membrane, rich in cholesterol and
functional proteins like calcium-pump, vitamin D receptor and
calcium-sensing receptors (8). In the absence of caveolae, pro-
teins normally expressed on the plasma membrane remain free
in the cytoplasm loosing their function. Knock-out mice for
caveolin-1 do not express calcium pump on their plasma mem-
brane, are hypercalciuric and develop tubular calcium deposits.
The third strain of knock-out mice does not express NHERF-1,
a protein modulating the function of renal carriers for uric acid,
phosphate, sodium and calcium reabsorption (9). NHERF-1 si-
lencing causes a sustained increase in calcium and urate ex-
cretion in the urine and the development papillary deposits of
calcium. 

















The fourth strain of knock-out mice lacks the proximal phosphate
carrier gene (sodium-phosphate cotransport, Npt2a) (10). These
mice develop a phenotype characterized by hypophosphatemia
due to tubular phosphate loss, hypercalciuria, rickets and kidney
stones. However, this strain is not a good model of human kid-
ney stones because the same phenotype occurs in humans only
after mutations of Npt2c carrier gene, a specific isoform of Npt2
phosphate carriers, different from Npt2a.
The fifth stone-forming knock-out mice strain does not ex-
press both osteopontin and Tamm-Horsfall protein and shows
modifications of tubular phosphate and oxalate handling (11).
Approximately 39.3% of these mice have papillary calcium
deposits, whereas this prevalence decreases to 10-15%
among mice lacking the expression of one of these two pro-
teins. This observation suggests a synergistic effect of osteo-
pontin and Tamm-Horsfall protein in inhibiting crystal adhe-
sion to the tubular wall. 
In addition to these knock-out mice models, a stone forming rat
strain was selected by inbreeding generations of the most hy-
percalciuric Sprague-Dawley rats. These rats (GHS) were spon-
taneously (genetically) hypercalciuric and produced calcium-
phosphate stones (12). GHS rats overexpress the vitamin D re-
ceptor in the intestine and have intestinal calcium hyperabsop-
tion and low bone mass. Despite our knowledge of their pheno-
type, the primary defect leading to kidney stones in GHS rats is
still unclear (13). A quantitative trait locus linked to kidney
stones was identified studying rats bred from GHS females and
normocalciuric Wistar-Kyoto rats. This trait locus was mapped
on chromosome 1 and explained 7% of the phenotypic vari-
ance. The expression profile in rats at different generations has
been studied by microarray bearing thousands of genes, but
findings of these experiments are of difficult interpretation (14). 
Studies in patients with kidney stones
Dent syndrome and familial hypomagnesaemia with hypercalci-
uria and nephrocalcinosis (FHHNC) are the most common
among the many monogenic diseases including kidney stones
in their phenotype (15, 16). Dent syndrome is due to mutations
of either chloride channel 5 or phosphatidylinositol 4,5-bisphos-
phate 5-phosphatase genes (mapped on the chromosomes
Xp11.22 and Xq26, respectively), while claudin 16 gene (chro-
mosome 3q27) is responsible of FHHNC (17-19). Mutations of
these genes are occasionally found in patients with calcium
stones. However, epidemiologic data suggest that idiopathic
kidney stones are likely to have a polygenic and heteroge-
neous background, although we still know very little about the
underlying genes. Studies concerning the transmission pattern
of kidney stones suggest that a small number of genes is likely
to be involved. The model proposed by Goodman et al. estab-
lished that no more than 3-4 genes contribute to stone produc-
tion and acting on calcium, oxalate and citrate excretion (20).
Another group of researchers hypothesized that one major
gene explained the largest proportion of calcium excretion vari-
ance in stone patients (21). Although these studies suggest the
contribution of major genes to the phenotype, the definition of a
transmission model for kidney stones is far to be defined and a
pattern without major genes but with multiple genes exerting
small and additive effects cannot be excluded and could cause
an increased susceptibility to kidney stones.  
The vitamin D receptor (VDR) is located on chromosome
12q12-14 and its product modulates vitamin D stimulation on
intestinal absorption of calcium, osteoblastic activity and other
vitamin D targets. The study of 303 pairs of French-Canadian
brothers showed that four of the six markers used to map the
Figure 1 - In proximal tubular cells, the complex VDR/Vitamin D activates the transcription of phosphoenol-pyruvatecarboxyl-kinase (FEPK) gene and
the function of citrate reabsorption carrier. Thus, vitamin D may decrease urinary citrate excretion. In intestinal cells, the complex VDR/Vitamin D
causes a rapid non-genomic and a genomic activation of calcium absorption that occurs through apical calcium channels (TRPV6), and basolateral
calcium pump. Calbindin (CBP) binds calcium ions in cytoplasm and carries them from the apical to the basolateral membrane. 
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VDR gene were in linkage with kidney stones (22). The same
chromosomal region was also found in linkage with kidney
stones in four Indian families, even though findings with the
same markers were not completely in agreement with those re-
ported by the French-Canadian study (23).
Another strategy was applied to study the association between
VDR gene polymorphisms and kidney stones. Polymorphisms
sited on intron 8 and exon 9, and at the transcription start
codon were at first tested and found associated with kidney
stones (24-26). Variant alleles at intron 8 and exon 9 polymor-
phisms correlated with the severity of the stone disease, being
associated with early age of onset and higher frequency of
stones (27). These findings may be explained by a lower uri-
nary excretion of citrate observed in stone patients bearing
variant alleles at these polymorphisms. Citrate metabolism may
be influenced by VDR polymorphisms, as the VDR-vitamin D
complex induces the transcription of phosphoenol-pyruvatecar-
boxyl-kinase gene. This kinase reduces citrate excretion by
stimulating citrate reabsorption through the apical membrane
carrier in proximal tubular cells (28). Through this mechanism
(Figure 1), activating polymorphisms of the VDR gene could af-
fect the clinical history of kidney stone patients. As it often oc-
curs in complex diseases, these findings were not replicated in
other studies (29, 30). This discrepancy may be accounted for
by different environmental conditions or the effect of other
genes masking the association between VDR and the pheno-
type (1). However, these studies have collected a significant
amount of data suggesting that the VDR gene is involved in
lithogenesis, although the mechanisms for this involvement is
not yet defined.
The calcium sensing receptor (CaSR), mapped on chromo-
some 3q13.3-21, has been hypothesized to play a role in stone
formation (31). CaSR is expressed throughout the nephron and
modulates the function of different tubular regions. It is activat-
ed by the increase of calcium ions in the extracellular fluid that
stimulates different G proteins and inhibits adenilate-cyclase to
trigger intracellular pathways controlling tubular functions.
CaSR activation inhibits calcium reabsorption in the ascending
limb and water reabsorption in the collecting duct, while it in-
creases phosphate reabsorption in the proximal tubule (32).
The role of CaSR in stone production may be mediated by
these tubular effects and was suggested by a case-control
study that found an association of kidney stones with the poly-
morphisms of the 5’-untranslated region and first intron of
CaSR gene in a large group of patients recruited in Italian
stone centres. This large region contains CaSR gene promot-
ers and polymorphic alleles of its sequence could modify the
effect of promoters or transcription factors and, thus, gene ex-
pression. This case-control study involved a large number of
individuals (over 500 patients and 600 controls) and it is cur-
rently the largest case-control study in the medical literature.
CaSR polymorphisms were not related with intermediate phe-
notypes typically found in stone formers, like hypercalciuria and
hypocitraturia, suggesting that CaSR could take part in the pro-
duction of Randall plaque in papillary interstitium or calcium
salt deposits in tubular lumen, the putative early events in litho-
genesis (33, 34). It is, however, noteworthy that no linkage was
observed between CaSR locus and kidney stones (35) in
Franch-Canadian siblings. 
In three families with hypercalciuric stone forming members, a
linkage study identified 1q23.3-24 as a locus possibly involved
in kidney stones (36). The subsequent association analysis in
cases and controls recognized that variant alleles at six poly-
morphisms of bicarbonate-sensitive adenylate-cyclase gene
(sAC) were more common in patients with stones (37). Despite
these findings the activity of sAC and whether sAC is involved
in stone formation or in hypercalciuria or both is still unknown.
Other studies have identified the polymorphisms of osteopontin
(38), urokinase (39), interleukin-1 receptor (40), epidermal
growth factor (41) and E-cadherin genes (42) as polymor-
phisms involved in calcium stone formation. The first two com-
pounds are salt precipitation inhibitors, while the interleukin-1
receptor could be involved in the tubular inflammation that
takes part to stone formation. Findings of these studies were
not replicated in subsequent research. 
Conclusions
We have reviewed the most relevant studies on the genes that
are potentially involved in the pathogenesis or may be consid-
ered markers of stone susceptibility. Although these studies
have collected interesting information about the mechanisms of
stone formation, we are, unfortunately, still unable to provide
reliable markers of susceptibility. Polymorphisms of VDR and
CaSR genes may be involved in the nephrolithiasis, but it is un-
certain which specific polymorphisms could be responsible.
Thus, further studies are required to better assess the involve-
ment of these or other genes and the interactions between dif-
ferent genes and between genes and environment. Only the
cooperation between stone centers will ensure the collection of
an adequate number of cases to identify groups of patients
with a specific intermediate phenotype and to warrant data
replicability. On the other hand, biotechnology progress today
allows genotyping a large number of DNA samples in a short
time and at a relatively low cost thanks to microarrays technol-
ogy that can also be applied to the study of gene expression.
Modern biotechnology requires specific and complex genetic-
statistical analyses that can be performed with dedicated bioin-
formatics expertise and workstations. The establishment of
large samples of carefully phenotyped patients and adequate
biotechnological facilities will allow our research focusing on a
relatively small number of loci with the potential of developing
screening tests capable of identifying individuals with an in-
creased susceptibility to calcium kidney stones.
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